论文部分内容阅读
病人和方法:本文由8个临床中心提供病例,计80例。病人由末次规则月经期第一天算起,不超过孕56大(平均6.4周),在治疗前,全部妊娠试验阳性。用单次阴道栓剂放置于病人阴道后穹窿处。栓剂基质为2.2gwitepsol含3 mg 15(S)-15甲基-PGF_2α甲酯加入0.025%水杨酸以保持配方的稳定性。栓剂放置后患者取仰卧位至少60分。以后10小时观察期允许自由活动。成功标准:在治疗后的14天中,有明显的子宫持续性出血,伴同hCG明显下降,妊娠试验阴性;随访期间不需要外科手术干预。计56例,占70%。失败标准:在治疗后的14天中,无子宫持续出血,hCG下降不明显,治疗后14天妊娠试验仍阳性,计15例,占18.75%。
Patients and Methods: This paper is provided by eight clinical centers in 80 cases. The patient counted from the first day of the last menstrual period, not exceeding the 56th pregnancy (mean, 6.4 weeks). All pregnancy tests were positive before treatment. With a single vaginal suppository placed in the patient’s vaginal fornix. The suppository base was 2.2 gwitepsol containing 3 mg of 15 (S) -15 methyl-PGF-2 [alpha] methyl ester with 0.025% salicylic acid added to maintain formulation stability. Suppository patients placed in supine position for at least 60 minutes. 10 hours after the observation period to allow free movement. Success criteria: In the 14 days after treatment, there was significant persistent uterine bleeding, accompanied by a significant decrease in hCG, pregnancy test negative; no surgical intervention during follow-up. 56 cases, accounting for 70%. Failure criteria: In the 14 days after treatment, no uterine bleeding, hCG decreased significantly, after 14 days of pregnancy test is still positive, accounting for 15 cases, accounting for 18.75%.